Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of biomarker of psoriasis vulgaris blood plasma in target drugs

A type of psoriasis vulgaris, biomarker technology, applied in the field of biomarker screening, can solve the problems of low resolution and low sensitivity

Pending Publication Date: 2018-03-30
JINAN UNIVERSITY
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Commonly used assay methods for finding biomarkers include nuclear magnetic resonance (nuclear magnetic resonance, NMR), gas chromatography-mass spectrometry (gas chromatography-mass spectrometry, GC-MS), liquid chromatography-mass spectrometry (liquid chromatography-mass spectrometry) spectrometry, LC-MS), etc. Among them, gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry all need standard substances to determine the structure of biomarkers, and when known biomarkers are required, the determination of each marker content, not applicable when biomarkers are unknown
In addition, the detection sensitivity and resolution of 1H-NMR technology are not high
In recent years, there have been many reports on biomarkers of psoriasis, but their sensitivity and specificity need to be further verified

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biomarker of psoriasis vulgaris blood plasma in target drugs
  • Application of biomarker of psoriasis vulgaris blood plasma in target drugs
  • Application of biomarker of psoriasis vulgaris blood plasma in target drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] (1) Establishment of imiquimod-induced mouse psoriasis model: 24 female BALB / c mice were adaptively fed for 3 days and anesthetized with 4% chloral hydrate (0.1ml / 10g) intraperitoneally, and their backs were excised. Hair, forming an exposed area with a size of about 2cm×3cm, was randomly divided into 2 groups, 12 in each group, which were blank group and model group. Blank group: smear 62.5mg of Vaseline ointment on the bare back of the mice every day, and at the same time, gavage with normal saline, 0.2mL / time / day, for 7 consecutive days. Model group: smear 5% IMQ cream 62.5mg on the bare back of the mice at regular intervals every day, and at the same time, gavage with normal saline, 0.2mL / time / day, for 7 consecutive days.

[0031] (2) Collection and processing of mouse plasma samples: the mice in each group were drawn on the 8th day, and after the mice were anesthetized by intraperitoneal injection of 4% chloral hydrate solution (0.1ml / 10g), the blood was taken from...

Embodiment 2

[0036] Except step (2), all the other steps are identical with embodiment 1.

[0037] (2) Collection and processing of mouse plasma samples: the mice in each group were drawn on the 8th day, and after the mice were anesthetized by intraperitoneal injection of 4% chloral hydrate solution (0.1ml / 10g), the blood was taken from the eyeballs of the mice, and released In the centrifuge tube containing EDTA, immediately after blood collection, gently invert and mix 5-6 times, let it stand for 2 hours, centrifuge (4°C, 4000r / min, 10min), take the supernatant and store it in a -80°C refrigerator until Measurement. Before analysis, put the mouse plasma sample at room temperature for about 20 minutes until completely thawed, draw 200 μL of plasma, add 200 μL of acetonitrile to it, vortex for 30 s, centrifuge (12000r / min, 10min, 4°C), and take 750 μL of supernatant , blow dry with nitrogen, reconstitute the residue with 100 μL of methanol-water (10:90, v / v), vortex for 30 s, centrifuge (...

Embodiment 3

[0039] Except step (2), all the other steps are identical with embodiment 1.

[0040] (2) Collection and processing of mouse plasma samples: the mice in each group were drawn on the 8th day, and after the mice were anesthetized by intraperitoneal injection of 4% chloral hydrate solution (0.1ml / 10g), the blood was taken from the eyeballs of the mice, and released In the centrifuge tube containing EDTA, immediately after blood collection, gently invert and mix 5-6 times, let it stand for 2 hours, centrifuge (4°C, 4000r / min, 10min), take the supernatant and store it in a -80°C refrigerator until Measurement. Before analysis, put the mouse plasma sample at room temperature for about 20 minutes until completely thawed, draw 200 μL of plasma, add 200 μL of methanol to it, vortex for 30 seconds, centrifuge (12000r / min, 10min, 4°C), and take 750 μL of supernatant , blow dry with nitrogen, redissolve the residue with 100 μL of acetonitrile-water (10:90, v / v), vortex for 30 s, centrifu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a biomarker of psoriasis vulgaris blood plasma in target drugs. The invention is characterized in that: the biomarker is one or at least two of threonine, leucine, phenylalanine, tryptophan, palmitamide, linoleic acid amide, oleamide, oleic acid, stearic amide, arachidonic acid, cis-11-eicosenamide, trans-13-docosenamide, N- Twenty-two alkenamide, N-linoleoyltaurine, lysophosphatidylcholine (18:3), lysophosphatidylcholine (18:2), uric acid, lysophosphatidylcholine (16:0), lysophosphatidylcholine (18:1), and lysophosphatidylcholine (18:0). The invention combines UPLC / Q-TOF MS technology with multivariate statistical analysis to look for the psoriasis vulgaris patient biomarker, the method is feasible, scientific and reasonable, and the found biomarkeris conducive to establishment of an individualized drug administration scheme.

Description

technical field [0001] The invention relates to the field of biomarker screening, in particular to the application of a biomarker in plasma of psoriasis vulgaris in its targeted drug. Background technique [0002] Psoriasis, commonly known as "psoriasis", is a common chronic inflammatory proliferative skin disease that easily relapses, accounting for about 2% to 3% of the global population. The main histopathological changes are hyperproliferation of epidermal keratinocytes, dilation and growth of dermal capillaries, and infiltration of T cells, dendritic cells, neutrophils, and other inflammatory cells. Clinically, it is generally divided into four types, namely, vulgaris, pustular, erythrodermic, and arthropathy, among which psoriasis vulgaris is the most common, and its typical skin lesions are red papules or plaques covered with multiple layers. Silvery white scales. Psoriasis vulgaris has a long course of disease, extensive skin lesions, and often recurrent attacks. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/02G01N30/06
CPCG01N30/02G01N30/06
Inventor 李沙沙吴晓松刘英
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com